Novel agent combination therapies in melanoma: talimogene laherparepvec, PV-10 & IMO-2125

Novel agent combination therapies in melanoma: talimogene laherparepvec, PV-10 & IMO-2125

VJOncology

1 year
68 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The treatment of melanoma is undergoing exciting advancements, as discussed here by Paolo Ascierto, MD, of the National Cancer Institute of Naples, Naples, Italy. Dr Ascierto highlights a promising area for further development: combination therapy. Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, he highlights the different combinations to be considered. He first points towards the combination of talimogene laherparepvec with ipilimumab (NCT01740297), and a newer combination with pembrolizumab (KEYNOTE-034; NCT02263508), before considering the investigational drug PV-10 (NCT02288897), and the TLR-9 antagonist IMO-2125 in combination with ipilimumab or pembrolizumab (ILLUMINATE-204; NCT02644967).
Up Next Autoplay
Investigational Melanoma Vaccine, Seviprotimut-L: Moving Forward
Investigational Melanoma Vaccine, Seviprotimut-L: Moving Forward
Category: Melanoma and Skin Cancer
2 Views
UVA Cancer Center 10 hours
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Category: Melanoma and Skin Cancer
11 Views
UVA Cancer Center 1 day
Annual meeting of the Society for Immunotherapy of Cancer (SITC) 2019 Polynoma Presenting Interim Phase III Evidence for Its Investigational Melanoma Vaccine, Seviprotimut-L
Annual meeting of the Society for Immunotherapy of Cancer (SITC) 2019 Polynoma Presenting Interim Phase III Evidence for Its Investigational Melanoma Vaccine, Seviprotimut-L
Category: Melanoma and Skin Cancer
24 Views
Cancer-News 2 weeks
Dual-function Virus Designed For Killing Tumor Cells and Helping Immune Cells
Dual-function Virus Designed For Killing Tumor Cells and Helping Immune Cells
Category: Melanoma and Skin Cancer
23 Views
Cancer-News 1 month
Will the CheckMate 204 data affect clinicians?
Will the CheckMate 204 data affect clinicians?
Category: Melanoma and Skin Cancer
11 Views
moasc 2 months
CheckMate 204 Study
CheckMate 204 Study
Category: Melanoma and Skin Cancer
11 Views
moasc 2 months
Clinicians could change the way they manage their patients
Clinicians could change the way they manage their patients
Category: Melanoma and Skin Cancer
3 Views
moasc 2 months
Fixing toxic therapy
Fixing toxic therapy
Category: Melanoma and Skin Cancer
8 Views
moasc 2 months
Alternate dosing for immunotherapy
Alternate dosing for immunotherapy
Category: Melanoma and Skin Cancer
2 Views
moasc 2 months
Is this data practice changing for clinicians?
Is this data practice changing for clinicians?
Category: Melanoma and Skin Cancer
1 Views
moasc 2 months